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Atherosclerotic cardiovascular disease (CVD) is a
leading cause of death in type 2 diabetics with
myocardial infarction and stroke responsible for twice as
many deaths in type 2 diabetics than non-diabetics. The
primary mechanism responsible for myocardial infarc-
tion and stroke is atherosclerotic plaque rupture.
Systemic inflammation is closely linked to atheroscle-
rotic inflammation and increases cardiovascular event
risk.1 Histologically, ruptured plaques display a
metabolically active lipid cores with a large inflamma-
tory component. Conventional plaque imaging methods
such as ultrasound, invasive, CT, and MR angiography
focus on morphological plaque features of vulnerability
but cannot directly assess the metabolic activity of the
plaque. 18F-FDG PET/CT is a hybrid imaging technique
using a radiolabeled analog of glucose (18-Fluorine
labeled to Fluorodeoxyglucose/18F-FDG) to provide
anatomical (CT) and metabolic (PET) information on
atherosclerotic plaque. Uptake of FDG has been shown
in numerous studies to correlate closely with plaque
macrophage burden. Recent large-scale studies suggest
that modulation of systemic and atherosclerotic inflam-
mation reduces cardiovascular events.2
In patients with type 2 diabetes, Pioglitazone (but
not Glimepiride) reduces atherosclerotic inflammation
as assessed by 18F-FDG PET/CT independent of its
hypoglycaemic effect.3 Therefore, identification of those
most likely to benefit from an anti-inflammatory
response to pioglitazone is likely to be beneficial.
In a cohort study of 38 reasonably well-controlled
type 2 diabetics on standard oral hypoglycaemic agents
(OHAs), Tahara et al. aimed to identify clinical vari-
ables that predicted reduction of coronary inflammation
after a 4-month treatment period with add-on Pioglita-
zone (n = 16) or Glimepiride (n = 22). At baseline and
4 months post add-on therapy, all patients underwent a
75 g oral glucose tolerance test (OGTT), fasting plasma
glucose (FPG) and insulin, 30-min, 60-min, 90-min, and
120-min postload plasma glucose, serum levels of pig-
ment epithelium-derived factor [PEDF (a novel marker
of insulin resistance)], and an 18F-FDG PET/CT.
Coronary inflammation was assessed through cal-
culation of standardized uptake values (SUV) within the
left main trunk (LMT) and divided by the SUV within
the superior vena cava to give a target-to-background
ratio (TBR) of atherosclerotic plaque to blood pool
uptake (LMT-TBR). As glucose is a competitive
antagonist of FDG, serum levels affect cellular uptake
therefore a correction was made for fasting plasma
glucose (FPG) on the day on scanning.
Add-on therapy reduced fasting, 30-, 60-, 90-, and
120-minute postload glucose along with HBA1c levels
and LMT-TBR. There was a significant and independent
correlation of baseline non-use of aspirin (p = 0.03),
baseline-elevated PEDF (R2 = -0.378, p = 0.019), D
PEDF (R2 = 0.379, p = 0.016), and D120-min glucose
(R2 = 0.436, p = 0.006) with an 11% reduction in
overall mean LMT-TBR values (2.17 ± 0.53 to
1.93 ± 0.55). The authors suggest baseline PEDF,
DPEDF and D120 min post prandial glucose and as
potential therapeutic targets to reduce coronary inflam-
mation in type 2 diabetics and that aspirin may reduce
the anti-inflammatory effect of pioglitazone.
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The study does, however, have limitations. LMT-
TBR values were only significant reduced when cor-
rected for FPG, which critically was not measured at the
same time as the PET/CT. This confounds the inter-
pretation of the data in 2 ways; firstly, FPG is influenced
by diabetic medications therefore the measured SUVs
could remain the same but the adjusted TBRs would
change based on the FPG value. Secondly, patients with
type 2 diabetes unsurprisingly have quite variable daily
plasma glucose levels therefore plasma glucose at the
time of the scan is highly likely to differ from the FPG
used to correct LMT-SUV. Interestingly, uncorrected
TBR values in the aorta and LMT were not significantly
reduced by either add-on therapy (LMT-TBR
1.44 ± 0.31 vs 1.45 ± 0.34, Aorta-TBR 1.55 ± 0.29 vs
1.48 ± 0.27). The legitimacy of the authors results
therefore heavily rely on the FPG at the time of the PET/
CT scan (which we do not know) and the validity of the
correction calculation.
Moreover, adjudication of FDG uptake within the
coronary arteries and particularly the LMT is challeng-
ing.4 Inadequate myocardial suppression and spill over
from the aortic root make confirmation of definite LMT
uptake difficult. The authors recognized this and
although attempts were made to compensate for
myocardial and aortic spill over, the limited spatial
resolution of human PET (6 mm) makes signal spill over
and sampling errors more likely when imaging smaller
vessels.
In a metanalysis of 10 RCTs, pioglitazone has been
shown to reduce major adverse cardiovascular events,
MI and stroke.5 Both insulin resistance and low-grade
inflammation are associated with atherosclerotic pro-
gression and this group has previously shown
pioglitazone to reduce atherosclerotic progression
through a reduction in carotid inflammation as assessed
by FDG PET/CT.6 However, despite insulin resistance
and post prandial hyperglycaemia being associated with
an elevated risk of cardiovascular events, there are no
definitive data to suggest its reduction prevents them.
The author’s choice of tracer (FDG) is widely
employed as a quantitative parameter of inflammatory
cell activity, however, importantly lacks specificity for
pro-inflammatory M1 macrophages. Other tracers, such
as 68Ga-DOTATATE are specific for the somatostatin
receptor 2 on M1 macrophages, have been used suc-
cessfully in coronary disease and may be better suited.7
11C-PK11195 is another inflammation targeted tracer
which binds to the translocator receptor protein within
the mitochondria of inflammatory cells. Uptake has been
shown to correlate closely with TSPO binding sites in
patients with carotid stenosis disease.8 Crucially, these
tracers do not have the problems associated with non-
specific uptake within the myocardium or glycolytically
active tissue outside of atherosclerotic cardiovascular
disease and we question whether FDG is the most suit-
able inflammation tracer to study in a diabetic
population.
Reducing insulin resistance, systemic and
atherosclerotic plaque inflammation are proven to
reduce cardiovascular events. Hybrid PET/CT and PET/
MR platforms now allow direct quantification of
atherosclerotic plaque inflammatory activity and allow
temporal tracking in response to systemic therapy.
Tahara et al. have identified novel clinical variables
which they believe may predict coronary inflammation
in a population particularly vulnerable to cardiovascular
events. We believe their findings should be interpreted
with caution and would welcome a replicate study with a
more specific inflammatory tracer unaffected by serum
glucose (such as 68Ga-DOTATATE). Replication of the
results would strengthen the case for a longitudinal
cohort study to assess whether modification of these
clinical variables translates to reduced coronary
inflammation and event rates.
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